Related Experiment Video
Updated: Aug 14, 2026
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Reduced-Dose Regorafenib for Recurrent Glioblastoma: A Safety and Outcome Analysis
Massimiliano Domenico Rizzaro1,2, Claudia Fanizzi2, Giorgio Fiore2
1Department of Pathophysiology and Transplantation, University of Milan, 20122 Milan, Italy.
Cancers
|August 13, 2026
Summary
Reduced-dose regorafenib (80 mg/day) is a feasible and safe option for recurrent IDH-wildtype glioblastoma patients. This approach showed promising outcomes with no permanent treatment discontinuation due to toxicity.
Area of Science:
- Neuro-oncology
- Clinical pharmacology
- Cancer treatment
Background:
- Recurrent glioblastoma presents a significant challenge with no standard treatment.
- Regorafenib shows potential but is limited by toxicity.
- This study focuses on reduced-dose regorafenib for recurrent IDH-wildtype glioblastoma.
Purpose of the Study:
- To evaluate the feasibility and safety of reduced-dose regorafenib.
- To assess clinical outcomes including survival and progression-free survival.
- To explore treatment exposure and dose modifications in this patient group.
Main Methods:
- Retrospective analysis of 21 patients with recurrent IDH-wildtype glioblastoma.
- Regorafenib initiated at 80 mg/day on a 3-weeks-on/1-week-off schedule.
- Assessment of overall survival (OS1, OS2) and progression-free survival (PFS1, PFS2), toxicity (CTCAE v5.0).
Main Results:
- Median PFS2 was 5 months; median OS2 was 6 months; median OS1 was 21 months.
- No grade ≥ 3 adverse events were reported.
- No patients permanently discontinued treatment due to toxicity.
Conclusions:
- Reduced-dose regorafenib is feasible and well-tolerated in selected recurrent glioblastoma patients.
- These findings are hypothesis-generating and support further investigation.
- Prospective studies are needed to confirm the role of individualized regorafenib dosing.
